What we do Strides Pharma Science Ltd is a global pharmaceutical company headquartered in Bengaluru, India, manufacturing and exporting a broad range of branded and generic pharmaceutical and nutraceutical products worldwide. |
Founded in 1,990 |
Market share Strong presence in US generics market with 73 products; holds top three rank in 36 products; expanding in regulated and emerging markets globally. |
Problem solved Provides affordable, high-quality pharmaceutical solutions including acute, chronic, and specialty drugs to improve healthcare access globally. |
Top clients or who we serve Serves global pharmaceutical markets including hospitals, retail pharmacies, governments, and institutional buyers (B2B and B2C). |
Key management Badree Komandur (MD & Group CEO), Peter Hardwick (CEO North America), Nandini Matiyani (EVP HR) |
Our journey and innovations Founded in 1990, evolved through mergers and acquisitions, expanded manufacturing to 8 units across 3 continents, with 230+ ANDAs filed. |
Where we operate Operates in over 100 countries, with major revenues from North America, Europe, Africa, Australia, and Asia. |
Top products or what we offer Wide portfolio including tablets, capsules, injectables, nasal sprays, soft gelatin capsules, and specialty pharmaceuticals. |
Top brands Key brands include Jointflex, Fergon, and Vanquish; strong pipeline in controlled substances and hormones segments. |
Raw materials needed Pharmaceutical active ingredients and excipients sourced globally for dosage form manufacturing. |
Raw materials supplier Multiple global suppliers, details confidential. |
Recurring vs cyclical contribution Revenue primarily recurring from pharmaceuticals sales with some cyclical tender-based institutional business. |
Our industry position Among top generic pharmaceutical players in regulated markets, strong foothold in US and emerging markets. |
Financial highlights FY25 Consolidated revenue ₹45,653 million, EBITDA ₹8,028 million, Net Profit ₹3,593 million, YoY revenue growth 17.2%, EBITDA margin 17.6%. |
Geographical revenue split North America 53.7%, Europe 21.7%, Africa 10.1%, Australia 9.6%, India & Asia smaller shares. |
Order book - |
Whats driving growth New product launches, regulatory approvals, expanding geographic footprint, strategic partnerships, and portfolio diversification. |
Our future plans Target US revenues of $400 million by FY28, invest in specialty segments, expand CDMO presence via OneSource. |
Our green promise Achieved S&P Global ESG rating 80/100, integrating sustainability principles into operations and governance. |
Our people and values Emphasizes talent development, diversity, culture of ethics and governance with a global workforce. |
Key challenges ahead Regulatory uncertainties, competition in generics market, currency fluctuations, and supply chain risks. |
Interesting facts First Indian specialty pharma CDMO covering biologics and complex injectables through OneSource CDMO. |
Risks and strategy Mitigates product approval delays and competitive risks via diversified portfolio, strong R&D and partnerships. |
